“These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option,” Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said in a statement.
“We look forward to working with regulatory authorities around the world to bring Imfinzi to lung cancer patients as soon as possible.”
U.S. regulators earlier this month approved durvalumab as a treatment for bladder cancer, marking the first commercial green light for the product, though its big commercial opportunity lies in previously untreated lung cancer.
AstraZeneca said that it was continuing to explore Imfinzi’s full potential both as a treatment by itself, as well as in combination with tremelimumab.
Results of that trial are due in the middle of the year, and could transform AstraZeneca’s business.